REAGENTS
 

NF-kB DISEASES

 

              On this page are listed several diseases in which activation of NF-kB has been implicated.  For general reviews on the role of NF-kB in disease, see Aradhya & Nelson (2001), Kumar et al (2004), Yamamoto & Gaynor (2002) or Baldwin (2001).  For specific diseases see the listed references, which can be found either on this site (under References) or at PubMed (through the linked references).

 

Table 1: General Diseases

Disease                                                         Review/Paper

Ageing                          Chung et al, 2002; Adler et al, 2007; Csizar et al, 2008 

Allergies                                                Cousins et al, 2008

Headaches                                                Reuter et al, 2003

Pain                                     Tegeder et al, 2004; Niederberger & Geisslinger, 2008

Complex Regional Pain Syndrome          Hettne et al, 2007

Cardiac Hypertrophy      Purcell & Molkentin, 2003; Freund et al, 2005; Sen & Roy, 2005

Muscular Dystrophy (type 2A)              Baghdiguian et al, 1999

Muscle wasting                                      Hasselgren, 2007

Catabolic disorders                                Holmes-McNary, 2002

Diabetes mellitus, Type 1                       Ho & Bray, 1999; Eldor et al, 2006  

Diabetes  mellitus, Type 2                 Yuan et al, 2001; Lehrke et al, 2004; Chen, 2005

Obesity                                                       Gil et al, 2007

Fetal Growth Retardation                      Mammon et al, 2005

Hypercholesterolemia                            Wilson et al, 2000

Atherosclerosis                                       Ross et al, 2001 ; Li & Gao, 2005

Heart Disease                                         Valen et al, 2001  

Chronic Heart Failure                             Frantz et al, 2003; Gong et al, 2007

Ischemia/reperfusion  Toledo-Pereyra et al, 2004; Nichols, 2004; Ridder & Schwaninger, 2008

Stroke                                                    Herrmann et al, 2005  

Cerebral aneurysm                                 Aoki et al, 2007; 2009  

Angina Pectoris                                      Ritchie, 1998 

Pulmonary Disease                                 Christman et al, 2000  

Cystic Fibrosis          Pollard et al, 2005; Carrabino et al, 2006; Rottner et al, 2007

Acid-induced Lung Injury                        Madjdpour et al, 2003

Pulmonary hypertension                         Sawada et al, 2007

Chronic Obstructive Pulmonary

            Disease (COPD)                         Barnes, 2002 ; Rahman & Kilty, 2006

Hyaline Membrane Disease                    Cheah et al, 2005

Kidney Disease                 Guijarro & Egido, 2001; Camici, 2006; Guzik & Harrison, 2007

Glomerular Disease                                Zheng et al, 2005

Alcoholic Liver Disease                        Zima & Kalousova, 2005

Leptospirosis renal disease                   Yang et al, 2001

Gut Diseases                                           Neurath et al, 1998  

Peritoneal endometriosis                 Gonzalez-Ramos et al, 2007

Skin Diseaes                                           Bell et al, 2003  

Nasal sinusitis                                       Xu et al, 2006

Anhidrotic Ecodermal Dysplasia-ID     Puel et al, 2005

Behcet's Disease                                   Todaro et al, 2005

Incontinentia pigmenti                           Courtois & Israel, 2000  

Tuberculosis                                          Zea et al, 2006

Asthma                                                   Pahl & Szelenyi, 2002

Arthritis   Roshak et al, 2002 ; Roman-Blas & Jimenez, 2006; Aud & Peng, 2006; Okamoto, 2006

Crohn's  Disease                                     Pena & Penate, 2002 

Colitis (rat)                                            Chen et al, 2005

Ocular Allergy                                       Bielory et al, 2002

Glaucoma                                               Zhou et al, 2005

Appendicitis                                           Pennington et al, 2000

Paget's Disease                                       Lin et al, 2007

Pancreatitis                                Weber & Adler, 2001 ; Gray et al, 2006

Periodonitis                                            Nichols et al, 2001; Ambili et al, 2005

Endometriosis                                         Guo, 2006; Celik et al, 2008

Inflammatory Bowel Disease                Dijkstra et al, 2002; Atreya et al, 2008  

Inflammatory Lung Disease                     Park & Christman, 2006

Sepsis                                                     Wratten et al, 2001; Abraham, 2003

Silica-induced                                        Chen & Shi, 2002  

Sleep apnoea                                          Lavie, 2003

AIDS (HIV-1)                                         Hiscott et al., 2001  

Autoimmunity                                Hayashi & Faustman, 2000; Bacher & Schmitz, 2004

Antiphospholipid Syndrome                   Lopez-Pedrera et al, 2005

Lupus                  Kammer & Tsokos, 2002 ; Okamoto, 2006; Oikonomidou et al, 2007 

Lupus nephritis                                       Zheng et al, 2006, 2008

Chronic Disease Syndrome                   Maes et al, 2007

Familial Mediterranean Fever               Onen, 2005

Hereditary Periodic Fever Syndrome        Jeru et al, 2008

Psychosocial stress diseases                  Bierhaus et al, 2004

Neuropathological Diseases Cechetto, 2001; Mattson & Camandola, 2001;                                                                                         Pizzi & Spano, 2006  

Familial amyloidotic polyneuropathy, inflamm neuropathy Mazzeo et al, 2004

Traumatic brain injury                           Hang et al, 2005

Spinal cord injury                                 Brambilla et al, 2005

Parkinson Disease                         Soos et al, 2004, Mogi et al, 2006

Multiple Sclerosis                            Satoh et al, 2007

Rheumatic Disease          Okamoto, 2006; Greetham et al, 2007

Alzheimers  Disease                     Mattson & Camandola, 2001; Collister & Albensi, 2005 

Amyotropic lateral sclerosis                  Xu et al, 2006

Huntington's Disease                              Khoshnan et al, 2004

Retinal Disease                                      Kitaoka et al, 2004

Cataracts                                                 Yang et al, 2006

Hearing loss                                   Merchant et al, 2005; Lang et al, 2006

Cancer       Gilmore et al, 2002; Karin et al, 2002: Lee et al, 2007 (see Table 2, below)

 ______________________________________________________________________

.

 

Table 2:  Constitutive activation of NF-kB in human cancer cells

Cancer type                                       Reference

A: Primary tumors and tumor cell lines

Solid tumors (generally)                      Pacifico & Leonardi, 2006

Breast                        Nakshatri et al, 1997; Sovak et al, 1997; Ahmed et al, 2006

Cervix               Nair et al, 2003; Kumar et al, 2005; Shehata, 2005; Ramdass et al, 2006

Ovary                                             Dejardin et al, 1999; Huang et al, 2000

Vulva                                              Seppanen & Vihko, 2000

Prostate   Huang et al, 2001; Palayoor et al, 1999; Fradet  et al, 2004; Lessard et al, 2006;  Paule et al, 2007

Kidney                                                 Oya et al, 2001, 2003

Bladder                   Horiguchi et al, 2003; Kadhim et al, 2006; Levidou et al, 2008

Lung    Tichelaar et al, 2004; Tang et al, 2006; Zhang et al, 2007; Motadi et al, 2007; Stathopoulos et al, 2008

Mesothelioma                       Bertino et al, 2007; Carbone & Bedrossian, 2006

Non small-cell lung     Zhang et al, 2006; Tew et al, 2007; Jin et al, 2008

Liver     Tai et al, 2000, Arsura & Cavin, 2005; Qiao et al, 2006; Seki & Brenner, 2007

Pancreas       Wang et al, 1999; Sclabas et al, 2003; Xiong, 2004; Jackson & Evers, 2006;

     Zhang & Rigas, 2006; Sarkar et al, 2006; Weichert et al, 2007; Sebens et al, 2008; Holcomb et al, 2008

Esophageal/gastric         Sutter et al, 2004; Lee et al, 2005; Abdel-Latif et al, 2005, 2008

                                                  Jackson & Evers, 2006: Levidou et al, 2007

Laryngeal                                            Zhu et al, 2004; Pan et al, 2005

Stomach                                              Sasaki et al, 2001; Wu et al, 2007

Colon              Lind et al, 2001; Schottelius & Dinter, 2006; Aranha et al, 2007

Thyroid           Visconti et al, 1997; Pacifico et al, 2004; Gombos et al, 2007

Parathyroid                                          Corbetta et al, 2004

Melanoma               Yang & Richmond, 2001; Torabian & Kashani-Sabet, 2005;  

      Amiri & Richmond, 2005; Ueda & Richmond, 2006; Van den Oord et al, 2007

Squamous cell carcinoma        Loercher et al, 2004; Kobielak & Fuchs, 2006

Head and neck                         Ondrey et al, 1999; Chung et al, 2006; Allen et al, 2007;

                                                        Jackson-Bernitsas et al, 2007

Endometrial (Uteris)                       Pallares et al, 2004; Domenyuk et al, 2007

Cylindromatosis Kovalenko et al, 2003; Brummelkamp et al, 2003; Trompouki et al, 2003

Brooke-Spiegler, Trichoepithelioma         Almeida et al, 2007

Hilar Cholangiocarcinoma                            Chen et al, 2005

Oral carcinoma  Nakayama et al, 2001; Bindhu et al, 2006; Mishra et al, 2006; Sawhney et al, 2007

                                   Min et al, 2007

Astrocytoma/glioblastoma                  Hayahsi et al, 2001; Garkavtsev et al, 2004

Neuroblastoma                    Bian et al, 2002; Brown et al, 2007; Widera et al, 2007 

Glioblastoma                                    Raychaudhuri et al, 2007; Smith et al, 2007

Hodgkin’s lymphoma                          Bargou et al, 1996, 1997; Staudt, 2000

Acute lymphoblastic leukemia            Kordes et al, 2000; Munzert et al, 2004

Acute myelogenous leukemia             Guzman et al, 2001; Fabre et al, 2007

Acute T-cell leukemia (+/-HTLV-1)       Arima & Tei, 2001; Horie et al, 2006  

Acute Non-lymphocytic leukemia                    Lei & Zhao, 2007

Chronic lymphocytic leukemia  Furman et al, 2000 ; Pickering et al, 2006; Herwamana et al, 2008

Burkitts Lymphoma (EBV)                              Knecht et al, 2001  

Mantle cell lymphoma                                     Martinez et al, 2003

Myelodysplastic syndrome                              Fabre et al, 2007

Multiple myeloma                                       Berenson et al, 2001; Gilmore, 2007

Diffuse large B-cell lymphoma                    Davis et al, 2001; Shaffer et al, 2002  

MALT lymphoma                                     Sagaert al, 2007; Inagaki, 2007; Du, 2007  

Waldenstrom macroglobulinemia                         Leleu et al, 2008

B: In vitro transformation of cells

AP12/MALT1             Stoffel et al, 2004; Ho et al, 2005; Lucas et al, 2007

BCR-ABL                                            Reuther et al, 1999  

BRAF                                                   Liu et al, 2007

DBL/DBS                                            Whitehead et al, 1999  

Muc1                                                   Ahmad et al, 2007

Notch1                                                 Vilimas et al, 2006 

Pim-2                                                   Fox et al, 2003; Hammerman et al, 2004

PDGF-beta chain                                Shimamura et al, 2002

RAF                                                     Baumann et al, 2000

RAS                                                     Finco et al, 1997  

RET/PTC3                                           Russell et al, 2003

TEL-JAK2                                           Santos et al, 2001

TEL-PDGFR                                        Besancon et al, 1998

Tio (herpesvirus)                                 Heinemann et al, 2006  

Vav                                                      Palmby et al, 2004  

 ______________________________________________________________________

 

Reference List

    Abdel-Latif MM, Kelleher D and Reynolds JV (2008) Potential role of NF-kB in esophageal adenocarcinoma: as an emerging molecular target. Journal of Surgical Research in press

     Abdel-Latif MM, O'Riordan JM, Ravi N, Kelleher D and Reynolds JV (2005) Activated nuclear factor-kB and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy. Diseases of Esophagus 18: 246-252

    Abraham E (2003) Nuclear factor-kB and its role in sepsis-associated organ failure. Journal of Infectious Diseases 187: S364-S369 

    Adler AS, Sinha S, Kawahara TL, Zhang JY, Segal E and Chang HY (2007) Motif module map reveals enforcement of aging by continual NF-kB activity. Genes & Development 21: 3244-3257

     Ahmed KM, Cao N and Li JJ (2006) HER-2 and NF-kB as the targets for therapy-resistant breast cancer. Anticancer Research 26: 4235-4243

    Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S and Kufe D (2007) MUC1 oncoprotein activates the IkB kinase beta complex and constitutive NF-kB signaling. Nature Cell Biology 9: 1419-1427

     Allen CT, Ricker JL, Chen Z and Van Waes C (2007) Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck.. Head & Neck 29: 959-971

   Ambili R, Santhi WS, Janam P, Nandakumar K and Pillai MR (2005) Expression of activated transcription factor nuclear factor-kB in periodontally diseased tissues. Journal of Periodontology 76: 1148-1153

Almeida S, Maillard C, Itin P, Hohl D and Huber M (2008) Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity. Journal of Investigative Dermatology 127: 587-593

    Amiri KI and Richmond A (2005) Role of nuclear factor-kB in melanoma. Cancer Metastasis Reviews 24: 301-313

   Aoki T, Kataoka H, Shimamura M, Nakagami H, Wakayama K, Moriwaki T, Ishibashi R, Nozaki K, Morishita R and Hashimoto N (2007) NF-kB is a key mediator of cerebral aneurysm formation. Circulation 116 2830-2840

   Aoki T, Kataoka H, Ishibashi R, Morishita R and Hashimoto N (2009) Reduced collagen biosynthesis is the hallmark of cerebral aneurysm: contribution of interleukin-1beta and NF-kB. Arteriosclerosis, Thrombosis, and Vascular Biology, in press

    Aradhya S and Nelson DL (2001) NF-kB signaling and human disease. Current Opinions in Genetics and Development 11: 300-306   

    Aranha MM, Borralho PM, Ravasco P, Moreira da Silva IKB, Correia L, Fernandes A, Camilo ME and Rodrigues CM (2007) NF-kB and apoptosis in colorectal tumourigenesis. European Journal of Clinical Investigation 37: 416-424

Arima N and Tei C (2001) HTLV-I Tax related dysfunction of cell cycle regulators and oncogenesis of adult T cell leukemia. Leukemia and Lymphoma 40: 267-278 Leukemia and Lymphoma 40: 267-278

    Arsura M and Cavin LG (2005) Nuclear factor-kB and liver carcinogenesis. Cancer Letters 229: 157-169

     Atreya I, Atreya R and Neurath MF (2008) NF-kB in inflammatory bowel disease. Journal of Internal Medicine 263: 591-596

Aud D and Peng SL (2006) Mechanisms of disease: transcription factors in inflammatory arthritis. Nature Clinical Practice: Rheumatology 2: 434-442

    Bacher S and Schmitz ML (2004) The NF-kB pathway as a potential target for autoimmune disease therapy. Current Pharmeutical Design 10: 2827-2837

    Baghdiguian S, Martin M, Richard I, Pons F, Astier C, Bourg N, Hay RT, Chemaly R, Halaby G, Loiselet J, Anderson LV, Lopez de Munain A, Fardeau M, Mangeat P, Beckmann JS and Lefranc G (1999) Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkB alpha/NF-kB pathway in limb-girdle muscular dystrophy type 2A . Nature Medicine 5: 503-511  [published erratum appears in Nature Medicine 1999 Jul;5(7):849]  

   Baldwin AS Jr (2001) Series introduction: the transcription factor NF-kB and human disease. Journal of Clinical Investigation 107: 3-6 

   Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K, Royer H-D, Scheidereit C and Dörken (1996) High-level nuclear NF-kB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 87: 4340-4347

   Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C and Dörkin B (1997) Constitutive NF-kB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. Journal of Clinical Investigation 100: 2961-2969

   Barnes PJ (2002) New treatments for COPD. Nature Reviews Drug Discovery 1: 437-446

   Baumann B, Weber CK, Troppmair J, Whiteside S, Israel A, Rapp UR and Wirth T (2000) Raf induces NF-kB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. Proceedings of the National Academy of Sciences USA 97: 4615-4620

   Bell S, Degitz K, Quirling M, Jilg N, Page S and Brand K (2003) Involvement of NF-kB signalling in skin physiology and disease. Cell Signaling 15: 1-7

   Berenson JR, Ma HM and Vescio R (2001) The role of nuclear factor-kB in the biology and treatment of multiple myeloma. Seminars in Oncology 28: 626-633

    Bertino P, Marconi A, Palumbo L, Bruni BM, Barbone D, Germano S, Dogan AU, Tassi GF, Porta C, Mutti L and Gaudino G (2007) Erionite and asbestos differently cause transformation of human mesothelial cells. International Journal of Cancer 121: 2766-2774

 

     Besancon F, Atfi A, Gespach C, Cayre YE and Bourgeade MF (1998) Evidence for a role of NF-kB in the survival of hematopoietic cells mediated by interleukin-3 and the oncogenic TEL/platelet-derived growth factor beta fusion protein.  Proceedings of the National Academy of Sciences USA 95: 8081-8086

   Bian X, Opipari Jr AW, Ratanaproeksa AB, Boltano AE, Lucas PC and Castle VP (2002) Constitutively active NF-kB is required for the survival of S-type neuroblastoma. Journal of Biological Chemistry 277: 42144-42150  

   Bielory L, Kempuraj D and Theoharides T (2002) Topical immunopharmacology of ocular allergies. Current Opinion in Allergy and Clinical Immunology 2: 435-445

   Bierhaus A, Humpert PM and Nawroth PP (2004) NF-kB as a molecular link between psychosocial stress and organ dysfunction. Pediatic Nephrology 19: 1189-1191

   Bindhu OS, Ramadas K, Sebastian P and Pillai MR (2006) High expression levels of nuclear factor kB and gelatinases in the tumorigenesis of oral squamous cell carcinoma. Head and Neck 28: 916-925

    Brambilla R, Bracchi-Ricard V, Hu WH, Frydel B, Bramwell A, Karmally S, Green EJ and Bethea JR (2005) Inhibition of astroglial nuclear factor kB reduces inflammation and improves functional recovery after spinal cord injury. Journal of Experimental Medicine 202: 145-156

   Brown RE, Tan D, Taylor JS, Miller M, Prichard JW and Kott MM (2007) Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kB pathways in high risk neuroblastoma, with cell cycle and protein analyte correlates. Annals of Clinical and Laboratory Science 37: 141-147

Brummelkamp TR, Nijman SMB, Cirac AMG and Bernards R (2003) Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kB. Nature 424: 797-801

   Camici M (2007) The Nephrotic Syndrome is an immunoinflammatory disorder. Medical Hypotheses 68: 900-905

     Carbone M and Bedrossian CW (2006) The pathogenesis of mesothelioma. Seminars in Diagnostic Pathology 23: 56-60

    Carrabino S, Carpani D, Livraghi A, Di Cicco M, Costantini D, Copreni E, Colombo C and Conese M (2006) Dysregulated interleukin-8 secretion and NF-kB activity in human cystic fibrosis nasal epithelial cells. Journal of Cystic Fibrosis 5: 113-119

  Cechetto DF (2001) Role of nuclear factor kappaB in neuropathological mechanisms. Progress in Brain Research 132: 391-404  

   Celik O, Hascalik S, Elter K, Tagluk ME, Gurates B and Aydin NE (2008) Combating endometriosis by blocking proteasome and nuclear factor kB pathways. Human Reproduction 23: 2458-2465

Cheah FC, Winterbourn CC, Darlow BA, Mocatta TJ and Vissers MC (2005) Nuclear factor kB activation in pulmonary leukocytes from infants with hyaline membrane disease: associations with chorioamnionitis and ureaplasma urealyticum colonization. Pediatric Research 57: 616-623

   Chen F (2005) Is NF-kB a culprit in type 2 diabetes? Biochemical and Biophysical Research Communications 332: 1-3

   Chen F and Shi X (2002) NF-kB, a pivotal transcription factor in silica-induced diseases. Molecular and Cellular Biochemistry 234-235: 169-176  

   Chen K, Long YM, Wang H, Lan L and Liu ZH (2005) Activation of nuclear factor-kappa B and effects of pyrrolidine dithiocarbamate on TNBS-induced rat colitis. World Journal of Gastroenterology 11: 1508-1514

   Chen RF, Li ZH, Kong XH and Chen JS (2005) Effect of mutated IkBa transfection on multidrug resistance in hilar cholangiocarcinoma cell lines. World Journal of Gastroenterology 11: 726-728

   Christman JW, Sadikot RT and Blackwell TS (2000) The role of nuclear factor-kB in pulmonary diseases. Chest 117: 1482-1487

   Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, Ang KK, El-Naggar AK, Zanation AM, Cmelak AJ, Levy S, Slebos RJ and Yarbrough WG (2006) Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Research 66 8210-8218

      Chung HY, Kim HJ, Kim KW, Choi JS and Yu BP (2002) Molecular inflammation hypothesis of aging based on the anti-aging mechanism of calorie restriction. Microscopy Research and Technique 59: 264-272  

   Collister KA and Albensi BC (2005) Potential therapeutic targets in the NF-kB pathway for Alzheimer's disease. Drug News Perspectives 18: 623-629

   Corbetta S, Vicentini L, Ferrero S, Lania A, Mantovani G, Cordella D, Beck-Peccoz P and Spada A (2005) Activity and function of the nuclear factor kB pathway in human parathyroid tumors. Endocrine Related Cancer 12: 929-937

    Courtois G and Israel A (2000) NF-kB defects in humans: the NEMO/incontinentia pigmenti connection. Sci STKE Nov 14 (58): PE1

    Cousins DJ, McDonald J and Lee TH (2008) Therapeutic approaches for control of transcription factors in allergic disease. Journal of Allergy and Clinical Immunology 121 803-809

   Csizar A, Wang M, Lakatta EG and Ungvari ZI (2008) Inflammation and endothelial dysfunction during aging: role of NF-kB. Journal of Applied Physiology, in press

    Davis RE, Brown KD, Siebenlist U and Staudt LM (2001) Constitutive nuclear factor kB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. Journal of Experimental Medicine 194: 1861-1874

    Dejardin E, Deregowski V, Chapelier M, Jacobs N, Gielen J, Merville M-P and Bours (1999) Regulation of NF-kB activity by IkB-related proteins in adenocarcinoma cells. Oncogene 18: 2567-2577

    Dijkstra G, Moshage H and Jansen PL (2002) Blockade of NF-kB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease? Scandinavian Journal of Gastroenterology Supplement 236: 37-41

    Domenyuk VP, Litovkin KV, Verbitskaya TG, Dubinia VGa dn Bubnov VV (2007) Identification of new DNA markers of endometrial cancer in patients from the Ukranian population. Experimental Oncology 29 85-93

      Du MQ (2007) MALT lymphoma: recent advances in aetiology and molecular genetics. Journal of Clinical and Experimental Hematology 47: 31-42

  Eldor R, Yeffet YK, Baum K, Doviner V, Amar D, Ben-Neriah Y, Christofon G, Peled A, Carel JC, Boitard C, Klein T, Serup P, Eizirik DL and Melloul D (2006) Conditional and specific NF-kB blockade protects pancreatic beta cells from diabetogenic agents. Proceedings of the National Academy of Sciences USA 103: 5072-5077

    Fabre C, Carvalho G, Tasdemir E, Braun T, Ades L, Grosjean J, Boehrer S, Metivier D, Souquere S, Pierron G, Fenaux P and Kroemer G (2007) NF-kB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 26: 4071-4083

    Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ and Baldwin Jr AS (1997) Oncogenic Ha-Ras-induced signaling activates NF-kB transcriptional activity, which is required for cellular transformation. Journal of Biological Chemistry 272: 24113-24116  

    Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA and Thompson CB (2003) The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes & Development 17: 1841-1854 

    Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AM and Saad F (2004) Nuclear factor-kB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clinical Cancer Research 10: 8460-8464 

    Frantz S, Fraccarollo D, Wagner H, Behr TM, Jung P, Angermann CE, Ertl G, Bauersachs J (2003) Sustained activation of nuclear factor kappaB and activator protein 1 in chronic heart failure. Cardiovascular Research 57: 749-756

    Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P, El-Jamali A, Dietz R, Scheidereit C and Bergmann MW (2005) Requirement of nuclear factor-kB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 111: 2319-2325

    Furman RR, Asgary Z, Mascarenhas JO, Liou HC and Schattner EJ (2000) Modulation of NF-kB activity and apoptosis in chronic lymphocytic leukemia B cells. Journal of Immunology 164: 2200-2206

    Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, Brown E, Barnett GH and Jain RK (2004) The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428: 328-332

     Gil A, Aguilera CM, Gil-Campos M and Canete R (2007) Altered signalling and gene expression associated with the immune system and the inflammatory response in obesity. British Journal of Nutition 98: S121-S126

    Gilmore TD (2007) Multiple myeloma: lusting for NF-kB. Cancer Cell 12 95-97

    Gilmore TD, Gapuzan M-E, Kalaitzidis D and Starczynowski D (2002) Rel/NF-kB/IkB signal transduction in the generation and treatment of human cancer. Cancer Letters 181: 1-9  

    Gombos K, Zele E, Kiss I, Varjas T, Puskas L, Kozma L, Juhasz F, Kovacs E, Szanyi I and Ember I (2007) Characterization of microarray gene expression profiles of early stage thyroid tumours. Cancer Genomics and Proteomics 4: 403-410

    Gong KZ, Song G, Speirs JP, Kelso EJ and Zhang ZG (2007) Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches. International Journal of Clinical Practice 61: 611-621

   Gonzalez-Ramos R, Donnez J, Defrere S, Leclercq I, Squifflet J, Lousse JC and Van Langendonckt A (2007) Nuclear factor-kB is constitutively activated in peritoneal endometriosis. Molecular Human Reproduction in press

    Gray KD, Simovic MO, Blackwell TS, Christman JW, May AK, Parman KS, Chapman WC and Stain SC (2006) Activation of nuclear factor kB and severe hepatic necrosis may mediate systemic inflammation in choline-deificient/ethionine-supplemented diet-induced pancreatitis. Pancrease 33: 260-267

      Greetham D, Ellis CD, Mewar D, Fearon U, Nic An Ultaigh S, Veale DJ, Guesdon F and Wilson AG (2007) Functional characterisation of NF-kB inhibitor-like protein 1 (NFkBIL1), a candidate susceptibility gene for rheumatoid arthritis. Human Molecular Genetics, in press

       Guijarro C and Egido J (2001) Transcription factor-kappaB (NF-kB) and renal disease. Kidney International 59: 415-424  

     Guo SW (2006) Nuclear factor-kB (NF-kB): an unsuspected major culprit in the pathogenesis of endometriosis that is still at large. Gynecology and Obstetrics Investigations 63: 71-97

    Guzik TJ and Harrison DG (2007) Endothelial NF-kB as a mediator of kidney damage: the missing link between systemic vascular and renal disease?  Circulation Research 101: 227-229

    Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM and Jordan CT (2001) Nuclear factor-kB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98: 2301-2307  

 

    Hammerman PS, Fox CJ, Cinalli RM, Xu A, Wagner JD, Lindsten T and Thompson CB (2004) Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kB activation. Cancer Research 64: 8341-8348

 

    Hang CH, Shi JX, Li JS, Li WQ and Yin HX (2005) Up-regulation of intestinal nuclear factor kB and intercellular adhesion molecule-1 following traumatic brain injury in rats. World Journal of Gastroenterology 11: 1149-1154

 

    Hasselgren PO (2007) Ubiquitination, phosphorylation and acetylation - triple threat in muscle wasting. Journal of Cellular Physiology 293: R1545-R1551

 

    Hayashi T and Faustman D (2002) Defective function of the proteasome in autoimmunity: involvement of impaired NF-kB activation. Diabetes Technology & Therapeutics 2: 415-428

    Hayashi S, Yamamoto M, Ueno Y, Ikeda K, Ohshima K, Soma G and Fukushima T (2001) Expression of nuclear factor-kB, tumor necrosis factor receptor type 1, and c-Myc in human astrocytomas. Neurologia Medico-Chirufica 41: 187-195  

    Heinemann S, Biesinger B, Fleckenstein B and Albrecht JC (2006) NF-kB signaling is induced by the oncoprotein tio through direct interaction with TRAF6. Journal of Biological Chemistry 281: 8565-8572

  Herrmann O, Baumann B, de Lorenzi R, Muhammad S, Zhang W, Kleesiek J, Malfertheiner M, Kohrmann M, Potrovita I, Maegele I, Beyer C, Bruke JR, Hasan MT, Bujard H, Wirth T, Pasparakis M and Schwaninger M (2005) IKK mediates ischemia-induced neuronal death. Nature Medicine 11: 13322-1329

     Herwamana S, Albhazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennaan P and Pepper C (2008) The NF-kB subunit, Rel A, is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukaemia and represents a promising therapeutic target. Blood in press

    Hettne KM, de Mos M, de Bruijn AG, Weeber M, Boyer S, van Mulligen EM, Cases M, Mestres J and van der Lei J (2007) Applied information retrieval and multidisciplinary research: new mechanistic hypotheses in Complex Regional Pain Syndrome. Journal of Biomedical Discovery and Collaboration 2: 2

    Hiscott J, Kwon H and Genin P (2001) Hostile takeovers: viral appropriation of the NF-kB pathway. Journal of Clinical Investigation 107: 143-151

    Ho E and Bray TM (1999) Antioxidants, NFkB activation, and diabetogenesis. Proceedings of the Society of Experimental Biology and Medicine 222: 205-213  

    Ho L, Davis RE, Conne B, Chappuis R, Berczy M, Mhawech P, Staudt LM and Schwaller J (2005) MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kB dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 105: 2891-2899

    Holcomb B, Yip-Schneider M and Schmidt CM (2008) The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancrease 36: 225-235

    Holmes-McNary M (2002) Nuclear factor kappaB signaling in catabolic disorders. Current Opinion in Clinical Nutrition and Metabolic Care 5: 255-263

     Horie R, Watanabe T and Umezawa K (2006) blocking NF-kB as a potential strategy to treat adult T-cell leukemia/lymphoma. Drug News & Perspectives 19: 201-209

     Horiguchi Y, Kuroda K, Nakashima J, Murai M and Umezawa K (2003) Antitumor effect of a novel nuclear factor-kB activation inhibitor in bladder cancer cells. Expert Reviews in Anticancer Therapy 3: 793-798

    Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ (2001) Blockade of NF-kB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20: 4188-4197

    Huang S, Robinson JB, DeGuzman A, Bucanna CD and Fidler IJ (2000) Blockade of nuclear factor-kB signaling inhibits angiogenesis and tumorigenicity of ovarian cancer cells by suppressing expression of vascular endothelial growth factor and Interleukin 8. Cancer Research 60: 5334-5339  

    Inagaki H (2007) Mucosa-associated lymphoid tissue lymphoma: Molecular pathogenesis and clinicopathological significance. Pathology International 57: 474-484

    Jackson L and Evers BM (2006) Chronic inflammation and pathogenesis of GI and pancreatic cancers. Cancer Treatment and Research 130: 39-65

    Jackson-Bernitsas DG, Ichikawa H, Takada Y, Myers JN, Lim XL, Darnay BG, Chaturvedi MM and Aggarwal BB (2007) Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene 26: 1385-1397

    Jeru I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, Lackmy-Port-Lis M, Grimpel E, Landman-Parker J, Hentgen V, Marlin S, McElreavey K, Sarkisian T, Grateau G, Alnemri ES and Amselem S (2008) Mutations in NALP12 cause hereditary fever syndromes. Proceedings of the National Academy of Sciences USA in press

Jin X, Wang Z, Qiu L, Zhang D, Guo Z, Gao Z, Deng C, Wang F, Wang S and Guo C (2008) Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer. Cancer Science in press

     Kadhim HS, AL-Jeboori TI and Tawfik MS (2006) Possible role of nuclear factor kB detected by in situ hybridization in the pathogenesis of transitional cell carcinoma of the bladder. Journal Medical Lebanais 54: 96-99

    Karin M, Cao Y, Greten FR and Li ZW (2002) NF-kB in cancer: from innocent bystander to major culprit. Nature Reviews Cancer 2: 301-310  

    Kammer GM and Tsokos GC (2002) Abnormal T lymphocyte signal transduction in systemic lupus erythematosus. Current Directions in Autoimmunity 5: 131-150  

   Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH and Patterson PH (2004) Activation of the IkB kinase complex and nuclear factor-kB contributes to mutant Huntingtin neurotoxicity. Journal of Neuroscience 24: 7999-8008

    Kitaoka Y, Kumai T, Kitaoka Y, Lam TT, Munemasa Y, Isenoumi K, Motoki M, Kuribayashi K, Kogo J, Kobayashi S and Ueno S (2004) Nuclear factor-kB p65 in NMDA-induced retinal neurotoxicity. Brain Research Molecular Brain Research 131: 8-16

    Knecht H, Berger C, Rothenberger S, Odermatt BF and Brousset P (2001) The role of Epstein-Barr virus in neoplastic transformation. Oncology 60: 289-302  

    Kobielak A & Fuchs E (2006) Links between alpha-catenin, NF-kB, and squamous cell carcinoma. Proceedings of the National Academy of Sciences 103: 2322-2327

    Kordes U, Krappmann D, Heissmeyer V, Ludwig WD and Scheidereit C (2000) Transcription factor NF-kB is constitutively active in acute lymphoblastic leukemia cells. Leukemia 14: 399-402  

    Kovalenko A, Chabie-Bessia C, Cantarella G, Israel A, Wallach D and Courtois G (2003) The tumour suppressor CYLD negatively regulates NF-kB signalling by deubiquitination. Nature 424: 801-805

     Kumar A, Takada Y, Boriek AM and Aggarwal BB (2004) Nuclear factor-kB: its role in health and disease. Journal of Molecular Medicine 82: 434-448

     Kumar B, Husain SA and Chandra B (2005) Constitutive activation of nuclear factor-kB: Preferential homodimerization of p50 subunits in cervical carcinoma. Frontiers in Bioscience 10: 1510-1519

     Lavie L (2003) Obstructive sleep apnoea syndrome - an oxidative stress disorder. Sleep Medicine Review 7: 35-51

     Lee BL, Lee HS, Jung J, Cho SJ, Chung HY, Kim WH, Jin YW, Kim CS and Nam SY (2005) Nuclear factor-kB activation correlates with better prognosis and Akt activation in human gastric cancer. Clinical Cancer Research 11 2518-2525

     Lee CH, Jeon YT, Kim SH and Song YS (2007) NF-kB as a potential molecular target for cancer therapy. Biofactors 29: 19-35

     Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ and Lazar MA (2004) An inflammatory cascade leading to hyperresistinemia in humans. PLoS Medicine 1: e45

     Lei HY and Zhao XL (2007) Clincal significance of NF-kB continual activity and expression of WT1 and MDR1 in acute nonlymphocytic leukemia. Zhongguo Shi Yan Xue Za Zhi 15 253-257

     Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melham MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzip TE, Hideshima T, Brown M, Anderson KC and Ghobrial IM (2008) Targeting NF-kB in Waldenstrom macroglobulinemia. Blood in press

   Lessard L, Karakiewicz PI, Bellon-Gagnon P, Alam-Fahmy M, Ismail HA, Mes-Masson AM and Saad F (2006) Nuclear localization of nuclear factor-kB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clinical Cancer Research 12: 5741-5745

     Levidou G, Korkolopoulou P, Nikiteas N, Tzanakis N, Thymara I, Saetta AA Tsigris C, Rallis G, Vlasis K and Patsouris E (2007) Expression of nuclear factor kB in human gastric carcinoma: relationship with IkBa and prognostic significance. Virchows Archiv 450: 519-527

  Levidou G, Saetta AA, Korkolopoulou P, Papanastasiou P, Gioti K, Pavlopoulos P, Diamantopoulou K, Thomas-Tsagli E, Xiromeritis K and Patsouris E (2008) Clinical significance of nuclear factor (NF)-kB levels in urothelial carcinoma of the urinary bladder. Virchows Archiv in press

     Li JJ and Gao RL (2005) Should atherosclerosis be considered a cancer of the vascular wall? Medical Hypotheses 64: 694-698

     Lin N, Uchi H, Moroi Y, Fukiwake N, Dainichi T, Takeuchi S, Takahara M, Tu Y, Furue M and Urabe K (2007) Expression of the p38 MAPK, NF-kB and cyclin D1 in extramammary Paget's disease. Journal of Dermatological Science 45: 187-192

      Lind DS, Hochwald SN, Malaty J, Rekkas S, Hebig P, Mishra G, Moldawer LL, Copeland EM 3rd and Mackay S (2001) Nuclear factor-kB is upregulated in colorectal cancer. Surgery 130: 363-369

     Liu J, Kumar KGS, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A and Fuchs SY (2007) Oncogenic BRAF regulates beta-Trcp expression and NF-kB activity in human melanoma cells. Oncogene 26: 1954-1958

     Loercher A, Lee TL, Ricker JL, Howard A, Geoghegen J, Chen Z, Sunwoo JB, Sitcheran R, Chuang EY, Mitchell JB, Baldwin AS Jr and Van Waes C (2004) Nuclear factor-kB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Research 64: 6511-6523

     Lopez-Pedrera C, Buendia P. Jose Cuadrado M, Siendones E, Angeles Aguire M, Barbarroja N, Montiel-Duarte C, Torres A, Khamashta M and Velasco F (2005) Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis and Rheumatism 54: 301-311

     Lucas PC, Kuffa P, Gu S, Kohrt D, Kim DS, Siu K, Jin X, Swenson J and McAllister-Lucas LM (2007) A dual role for the API2 moiety in API2-MALT1-dependent NF-kB activation: heterotypci oligomerization and TRAF2 recruitment. Oncogene in press

      Madjdpour L, Kneller S, Booy C, Pasch T, Schimmer RC and Beck-Schimmer B (2003) Acid-induced lung injury: role of Nuclear Factor-kB. Anesthesiology 99: 1323-1332

     Maes M, Mihaylova I and Bosmans E (2007) Not in the mind of the neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappaB. Neuro Endocinol Letters 28: 456-462

     Mammon K, Keshet R, Savion S, Pekar O, Zaslavsky Z, Fein A, Toder V and Torchinsky A (2005)  Diabetes-induced fetal growth retardation is associated with suppression of NF-kB activity in embryos. Review of Diabetic Studies 2 27-34

     Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E, Martin P, Martinez-Climent JA, Garcia-Conde J, Menarguez J, Solano F, Mollejo M and Piris MA (2003) The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Research 63: 8226-8232

     Mattson MP and Camandola S (2001) NF-kB in neuronal plasticity and neurodegenerative disorders. Journal of Clinical Investigation 107: 247-254  

     Mazzeo A, Aguennouz M, Messina C and Vita G (2004) Immunolocalization and activation of transcription factor nuclear factor kB in dysimmune neuropathies and familial amyloidotic polyneuropathy. Archives of Neurology 61: 1097-1102

     Merchant SN, Adams JC and  Nadol JB Jr (2005) Pathology and pathophysiology of idiopathic sudden sensorineural hearing loss. Otology and Neurotology 26: 151-160

    Min R, Tong J, Wenjun Y, Wenhu D, Xiaojian Z, Jiacai H, Jian Z, Wantao C and Chenping Z (2007) Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by shikonin was partly through the inactivation of NF-kB pathway. Phytotherapy Research in press

Mishra A, Bharti AC, Varghese P, Saluja D and Das BC (2006) Differential expression and activation of NF-kB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection. International Journal of Cancer 119: 2840-2850

     Mogi M, Kondo T, Mizuno T and Nagatsu T (2007) p53 protein, interferon-gamma, and NF-kB levels are elevated in the Parkinsonian brain. Neuroscience Letters 414: 94-97

     Motadi LR, Misso NL, Dlamini Z and Bhoola KD (2007) Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets. International Immunopharmacology 7: 1934-1947

    Munzert G, Kirchner D, Ottmann O, Bergmann L and Schmid RM (2004) Constitutive NF-kB/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Leukemia and Lymphoma 45: 1181-1184

     Nair A, Venkatraman M, Maliekal TT, Nair B and Karunagaran D (2003) NF-kB is constitutively activated in high- grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 22: 50-58  

     Nakayama H, Ikebe T, Beppu M and Shirasuma K (2001) High expression levels of nuclear factor kB, IkB kinase b and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 92: 3037-3044

     Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ and Sledge Jr GW (1997) Constitutive activation of NF-kB during progression of breast cancer to hormone-independent growth. Molecular and Cellular Biology 17: 3629-3639

     Niederberger E and Geisslinger G (2008) The IKK-NF-kB pathway: a source for novel molecular drug targets in pain therapy? FASEB Journal, in press

Neurath MF, Becker C and Barbulescu K (1998) Role of NF-kB in immune and inflammatory responses in the gut. Gut 43: 856-860

     Nichols TC, Fischer TH, Deliargyris EN and Baldwin Jr AS (2001) Role of nuclear factor-kappaB (NF-kB) in inflammation, periodontitis, and atherogenesis. Annals of Periodontology 6: 20-29  

     Nichols TC (2004) NF-kB and reperfusion injury. Drug News and Perspectives 17: 99-104

     Oikonomidou O, Vlachoyiannopoulos PG, Kominakis A, Kalofoutis A, Moutsopoulos HM and Moutsatsou P (2007) Glucocorticoid receptor, nuclear factor kB, activator protein-1 and c-Jun N-terminal kinase in systemic lupus erythematosus patients. Neuroimmunomodulation 13 194-204

      Okamoto T (2006) NF-kB and rheumatic diseases. Endocrine, Metabolic & Immune Disorders: Drug Targets 6: 359-372

      Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV, Mukaida N and Van Waes C (1999) Constitutive activation of transcription factors NF-kB, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Molecular Carcinogenesis 26: 119-129  

     Onen F (2006) Familial Mediterranean Fever. Rheumatology International 26: 489-496

     O'Neil BH, Buzkova P, Farrah H, Kashatus D, Sanoff H, Goldberg RM, Baldwin AS and Funkhouser WK (2007) Expression of nuclear factor-kB family proteins in hepatocellular carcinomas. Oncology 72: 97-104

Oya M, Ohtsubo M, Takayanagi A, Tachibana M, Shimizu N and Murai M (2001) Constitutive activation of NF-kB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 20: 3888-3896 

     Oya M, Takayanagi A, Horiguchi A, Mizuno R, Ohtsubo M, Marumo K, Shimizu N and Murai M (2003) Increased nuclear factor kappaB activation is related to tumor development of renal cell carcinoma. Carcinogenesis 24: 377-384

     Pacifico F and Leonardi A (2006) NF-kB in solid tumors. Biochemical Pharmacology 72: 1142-1152  

     Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, Chiappetta G, Terrazzano G, Liguoro D, Vito P, Consiglio E, Formisano S and Leonardi A (2004) Oncogenic and anti-apoptotic activity of NF-kB in human thyroid carcinomas. Journal of Biological Chemistry 279: 54610-54619

     Pahl A and Szelenyi I (2002) Asthma therapy in the new millennium. Inflammation Research 51: 273-282

     Palayoor ST, Yourmell MY, Calderwood SK, Coleman CN and Price BD (1999) Constitutive activation of IkB kinase b and NF-kB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18: 7389-7394

     Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J and Matias-Guiu X (2004) Abnormalities in the NF-kB family and related proteins in endometrial carcinoma. Journal of Pathology 204: 595-577

     Palmby TR, Abe K, Karnoub AE and Der CJ (2005) Vav transformation requires activation of multiple GTPases and regulation of gene expression. Molecular Cancer Research 2: 702-711

     Pan S, Tao Z, Wu L, Xiao B and Chen S (2005) Nuclear factor kB/p65 and cyclooxygenase-2 expression and clinic significance in human laryngeal squamous cell carcinoma [Article in Chinese]. Lin Chuang Er Bi Yan Hou Ke Za Zhi 19: 535-537

     Park Gy and Christman JW (2006) Nuclear factor kB is a promising therapeutic target in inflammatory lung disease. Current Drug Targets 7: 661-668

     Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F and de la Taille A (2007) The NF-kB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World Journal of Urology 25: 477-489

      Pena AS and Penate M (2002) Genetic susceptibility and regulation of inflammation in Crohn's disease. Relationship with the innate immune system [Article in English, Spanish]. Revista Espanola d Enfermedades Digestivas 94: 351-360  

     Pennington C, Dunn J, Li C, Ha T and Browder W (2000) Nuclear factor kB activation in acute appendicitis: a molecular marker for extent of disease? American Surgery 66: 914-918

     Pickering BM, de Mel S, Lee M, Howell M, Habens F, Dallman CL, Neville LA, POtter KN, Mann J, Mann DA, Johnson PW, Stevenson FK and Packham G (2007) Pharmacological inhibitors of NF-kB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 26: 1166-1177

    Pizzi M and Spano P (2006) Distinct roles of diverse nuclear factor kB complexes in neuropathological mechanisms. European Journal of Pharmacology 545: 22-28

     Pollard HB, Ji XD, Jozwik C and Jacobowitz DM (2005) High abundance protein profiling of cystic fibrosis lung epithelial cells. Proteomics 5: 2210-2216

     Puel A, Yang K, Ku CL, von Bernuth H, Bustamante J, Santos OF, Lawrence T, Chang HH, Al-Mousa H, PIcard C and Casonova JL (2005)  Heritable defects of the human TLR signalling pathways. Journal of Endotoxin Research 11: 220-224

     Purcell NH and Molkentin JD (2003) Is nuclear factor kappaB an attractive therapeutic target for treating cardiac hypertrophy? Circulation 108: 638-640

     Qiao L, Zhang H, Yu J, Francisco R, Dent P, Ebert MP, Rocke C and Farrell G (2006) Constitutive activation of NF-kB in human hepatocellular carcinoma: evidence of a cytoprotective role. Human Gene Therapy 17 280-290

    Rahman I and Kilty I (2006) Antioxidant therpaeutic targets in COPD. Current Drug Targets 7: 707-720

     Ramdass B, Maliekal TT, Lakshmi S, Rehman M, Rema P, Nair P, Mukherjee G, Reddy BK, Krishna S and Radakrishna Pillai M (2007) Coexpression of Notch1 and NF-kB signalling pathway components in human cervical cancer progression. Gynecologic Oncology 104: 352-361

    Raychaudhuri B, Han Y, Lu T and Vogelbaum MA (2007) Aberrant constitutive activation of nuclear factor kB in glioblastoma multiforme drives invasive phenotype. Journal of Neurooncology 85: 39-47

Reuter U, Chiarugi A, Bolay H and Moskowitz MA (2006) Nuclear factor-kB a s a molecular target for migraine therapy. Headache 43: 426-427

     Reuther JY, Reuther GW, Cortez D, Pendergast AM and Baldwin Jr AS (1998)  A requirement for NF-kB activation in Bcr-Abl mediated transformation. Genes & Development 12: 968-981  

     Ridder DA, Schwaninger M (2008) NF-kB signaling in cerebral ischemia. Neuroscience in press

    Ritchie ME (1998) Nuclear factor kappaB is markedly and selectively activated in humans with unstable angina pectoris. Circulation 98: 1707-1713

     Roman-Blas JA and Jimenez SA (2006) NF-kB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis  and Cartilage 14 839-848

    Roshak AK, Callahan JF and Blake SM (2002) Small-molecule inhibitors of NF-kB for the treatment of inflammatory joint disease. Current Opinion in Pharmacology 2: 316-321

    Ross JS, Stagliano NE, Donovan MJ, Breitbart RE and Ginsburg GS (2001) Atherosclerosis: a cancer of the blood vessels? American Journal of Clinical Pathology 116: S97-S107  

    Rottner M, Kunzelmann C, Mergey M, Freyssinet JM and Martinez MC (2007) Exaggerated apoptosis and NF-kB activation in pancreatic and tracheal cystic fibrosis cells. FASEB Journal 21: 2939-2948

    Russell JP, Shinohara S, Melillo RM, Castellone MD, Santoro M and Rothstein JL (2003) Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. Oncogene 22: 4569-4577

    Santos SC, Monni R, Bouchaert I, Bernard O, Gisselbrecht S, Gouilleux F and Penard-Lacronique V (2001) Involvement of the NF-kB pathway in the transforming properties of the TEL-Jak2 leukemogenic fusion protein. FEBS Letters 497: 148-152

    Sagaert X, De Wolf-Peeters C, Noels H and Baens M (2007) The pathogenesis of MALT lymphomas: where do we stand? Leukemia 21: 389-396

    Sarkar FH, Banerjee S and Li Y (2006) Pancreatic cancer: pathogenesis, prevention and treatment. Toxicology and Applied Pharmacology in press

    Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, Nakamura K, Yamanaka T, Uchiyama A, Tanaka M and Katano M (2001) Nuclear factor-kB p65 (RelA) transcription factor is constitutively activated in human gastric carcimoma tissue. Clinical Cancer Research 7: 4136-4142  

    Satoh JI, Illes Z, Peterfalvi A, Tabunoki H, Rozsa C and Yamamura T (2007) Aberrant transcriptional regulatory network in T cells of multiple sclerosis. Neuroscience Letters 422: 30-33

     Sawada H, Mitani Y, Maruyama J, Jiang BH, Ikeyama Y, Dida FA, Yamamoto H, Imanaka-Yoshida K, Shimpo H, Mizoguchi A, Maruyama K and Komada Y (2007) A nuclear factor-kB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest 132: 1265-1274

    Sawhney M, Rohatgi N, Kaur J, Shishodia S, Sethi G, Gupta SD, Deo SV, Shukla NK, Aggarwal BB and Ralhan R (2007) Expression of NF-kB parallels COX-2 expression in oral precancer and cancer: Association with smokeless tobacco. International Journal of Cancer 120: 2545-2556

     Sclabas GM, Fujioka S, Schmidt C, Evans DB and Chiao PJ (2003) NF-kB in pancreatic cancer. International Journal of Gastrointestinal Cancer 33: 15-26 

    Schottelius AJ and Dinter H (2006) Cytokines, NF-kB, microenvironment, intestinal inflammation and cancer. Cancer Treatment and Research 130: 67-87

   Sebens S, Arlt A and Schafer H (2008) NF-kB as a molecular target in the therapy of pancreatic cancer. Recent Results in Cancer Research 177: 151-164

     Seki E, and Brenner DA (2007) The role of NF-kB in hepatocarcinogenesis: promoter or suppressor? Journal of Hepatology 47: 307-309

     Sen CK and Roy S (2005) Relief from a heavy heart: redox-sensitive NF-kB as a therapeutic target in managing cardiac hypertrophy. American Journal of Physiology: Heart and Circulatory Physiology 289: H17-H19

    Seppanen M and Vihko KK (2000) Activation of transcription factor NF-kB by growth inhibitory cytokines in vulvar carcinoma cells. Immunology Letters 74: 103-109

    Shaffer AL, Rosenwald A and Staudt LM (2002) Lymphoid malignancies: the dark side of B-cell differentiation. Nature Review Immunology 2: 920-933  

  Shehata MF (2005) Rel/Nuclear factor kappaB apoptosis pathways in human cervical cancer cells. Cancer Cell International 5: 10

    Shimamura T, Hsu TC, Colburn NH and Bejcek BE (2002) Activation of NF-kB is required for PDGF-B chain to transform NIH3T3 cells. Experimental Cell Research 274: 157-167

    Smith D, Shimamura T, Barbera S and Bejcek BE (2007) NF-kB controls growth of glioblastomas/astrocytomas. Molecular and Cellular Biochemistry in press

    Soos J, Engelhardt JI, Siklos L, Hayas L and Majtenyi K (2004) The expression of PARP, NF-kB and parvalbumin is increased in Parkinson disease. Neuroreport 15 1715-1718

    Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM and Sonenshein GE (1997) Aberrant nuclear factor-kB/Rel expression and the pathogenesis of breast cancer. Journal of Clinical Investigation 100: 2952-2960

    Stathopoulos Gt, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS and Fingleton B (2008) Host nuclear factor-kB activation potentiates lung cancer metastasis. Molecular Cancer Research 6: 364-371

Staudt LM (2000) The molecular and cellular origins of Hodgkin’s disease. Journal of Experimental Medicine 191: 207-212

    Stoffel A, Chaurushiya M, Singh B and Levine AJ (2004) Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. Proceedings of the National Academy of Sciences USA 101: 9079-9084

   Sutter AP, Zeitz M and Scherubl H (2004) Recent results in understanding molecular pathways in the medical treatment of esophageal and gastric cancer. Onkologie 27: 17-21

 

    Tai DI, Tsai SL, Chang YH, Huang SN, Chen TC, Chang KS and Liaw YF (2000) Constitutive activation of nuclear factor kB in hepatocellular carcinoma. Cancer 89: 2274-2281

 

    Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB and Wistuba II (2006) Nuclear factor-kB (NF-kB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer: 107: 2637-2646

 

    Tegeder I, Niederberger E, Schmidt R, Kunz S, Guhring H, Ritzeler O, Michaelis M and Geisslinger G (2004) Specific Inhibition of IkB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. Journal of Neuroscience 24: 1637-1645

 

    Tew GW, Lorimer EL, Berg TJ, Zhi H, Li R and Williams CL (2007) SmgGDS regulates cell proliferation, migration, and NF-kB transcriptional activity in non-small cell lung carcinoma. Journal of Biological Chemistry, in press

 

    Torabian S and Kashani-Sabet M (2005) Biomarkers for melanoma. Current Opinions in Oncology 17: 167-171   

    Tichelaar JW, Zhang Y, LeRice JC, Lam S and Anderson MW (2004) Activation of the Akt/Nuclear Factor-kB signaling axis in developing lung neoplasia. Chest 125: 153S

 

    Todaro M, Zerilli M, Triolo G, Iovino F, Patti M, Accardo-Palumbo A, Gaudio FD, Turco MC, Petrella A, Maria RD and Stassi G (2005) NF-kB protects Behcet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis and Rheumatism 52: 2179-2191

 

    Toledo-Pereyra LH, Toledo AH, Walsh J and Lopez-Neblina F (2004) Molecular signaling pathways in ischemia/reperfusion. Experimental and Clincal Transplantation  2: 174-177

 

    Trompouki E, Hatzivassillou E, Tsichritzis T, Farmer H, Ashworth A and Mosialos G (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kB activation by TNFR family members. Nature 424: 793-796

 

    Ueda Y & Richmond A (2006) NF-kB activation in melanoma. Pigment Cell Research 19: 112-124

 

    Valen G, Yan ZQ and Hansson GK (2001) Nuclear factor kB and the heart. Journal of the American College of Cardiology 38: 307-314  

 

     Van den Oord JJ, Sarasin A, Winnepenninckx V and Spatz A (2007) Expression profiling of melanoma cell lines: in search of a progression-related molecular signature. Future Oncology 3: 609-611

   

  Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F, Thompson B, Spaulding C, Macaroun S, Alegre ML, Kee BL, Ferrando A, Miele L and Aifantis I (2006) Targeting the NF-kB signaling pathway in Notch1-induced T-cell leukemia. Nature Medicine 13: 70-77

    Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, Miano MP, de Nigris F, Casalino L, Curcio F, Santoro M and Fusco A (1997) Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkB p65 protein expression. Oncogene 15: 1987-1994

    Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary K and Chiao PJ (1999) The NF-kB RelA transcription factor is constiutively activated in human pancreatic adenocarcinoma cells. Clinical Cancer Research 5: 119-127

    Weber CK and Adler G (2001) From acinar cell damage to systemic inflammatory response: current concepts in pancreatitis. Pancreatology 1: 356-362

    Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, Denkert C, Imre G, Weller C, Hofmann HP, Niesporek S, Jacob J, Dietel M, Scheidereit C and Kristiansen G (2007) High expression of RelA/p65 is associated with activation of nuclear factor-kB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. British Journal of Cancer 97: 523-530

    Whitehead IP, Lambert QT, Glaven JA, Abe K, Rossman KL, Mahon GM, Trzaskos JM, Kay R, Campbell SL and Der CJ (1999) Dependence of Dbl and Dbs transformation on MEK and NF-kB activation. Molecular and Cellular Biology 19: 7759-7770  

     Widera D, Kaus A, Kaltschmidt C and Kaltschmidt B (2007) Neural stem cells, inflammation and NF-kB: basic principle of maintenance and repair or origin of brain tumours? Journal of Cellular and Molecular Medicine in press

    Wilson SH, Caplice NM, Simari RD, Holmes Jr DR, Carlson PJ and Lerman A (2000) Activated nuclear factor-kB is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis 148: 23-30  

    Wratten ML, Brendolan A, Ronco C, La Greca G and Tetta C (2001) Should we target signal pathways instead of single mediators in the treatment of sepsis? Contributions to Nephrology 132: 400-414

      Wu L, Pu Z, Feng J, Li G, Zheng Z and Shen W (2007) The ubiquitin-proteasome pathway and enhanced activity of NF-kB in gastric carcinoma. Journal of Surgical Oncology in press  

    Xiong HQ (2004) Molecular targeting therapy for pancreatic cancer. Cancer Chemotherapy and Pharmacology 54: S69-S77

    Xu R, Xu G, Shi J and Wen W (2007) A correlative study of NF-kB activity and cytokines expression in human chronic nasal sinusitis. Journal of Laryngology and Otology 121: 644-649

    Xu Z, Chen S, Li X, Luo G, Li L and Le W (2006) Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis. Neurochemistry Research 31: 1263-1269

    Yamamoto Y and Gaynor RB (2001) Role of the NF-kB pathway in the pathogenesis of human disease states. Current Molecular Medicine 1: 287-296

    Yang CW, Wu MS and Pan MJ (2001) Leptospirosis renal disease. Nephrology Dialysis Transplantation 16 Suppl 5: 73-77

    Yang J and Richmond A (2001) Constitutive IkB kinase activity correlates with nuclear factor-kB activation in human melanoma cells. Cancer Research 61: 4901-4909

    Yang Q, Zhao GQ, Li Q and Liu XP (2006) Expression of nuclear factor-kB in traumatic cataract. Chinese Journal of Traumatology 9: 86-90

    Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M and Shoelson SE (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKb. Science 293: 1673-1677

     Zea AH, Culotta KS, Ali J, Mason C, Park HJ, Zabaleta J, Garcia LF and Ochoa AC (2006) Decreased expression of CD3 zeta and nuclear transcription factor kB in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. Journal of Infectious Diseases 194: 1385-1393

     Zhang D, Jin X, Wang F, Wang S, Deng C, Gao Z and Guo C (2007) Combined prognostic value of both RelA and IkB-a expression in human non-small cell lung cancer. Annals of Surgical Oncology, in press

  Zhang Z, Ma J, Li N, Sun N and Wang C (2006) Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer. Annals of Thoracic Surgery 82 243-248

     Zhang Z and Rigas B (2006) NF-kB, inflammation and pancreatic carcinogenesis: NF-kB as a chemoprevention target. International Journal of Oncology 29: 185-192

    Zheng L, Sinniah R and Hsu SI-H (2005) In situ glomerular expression of activated NF-kB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy. Virchows Archiv 448: 172-183

   Zheng L, Sinniah R and Hsu SI-H (2006) Renal cell apoptosis and proliferation may be linked to nuclear factor-kappaB activation and expression of inducible nitric oxide synthase in patients with lupus nephritis.  Human Pathology 37: 637-647

 Zheng L, Sinniah R and Hsu SI (2008) Pathogenic role of NF-kB activation in tubulointerstitial inflammatory lesions in human lupus nephritis. Journal of Histochemistry and Cytochemistry, in press

   Zhou X, Li F, Kong L, Tomita H, Li C and Cao W (2005) Involvement of inflammation, degradation and apoptosis in a mouse model of glaucoma. Journal of Biological Chemistry 280: 31240-31248

   Zhu J, Hu G and Sun Y (2004) Expression and significance of nuclear factor kB in laryngeal carcinoma [Article in Chinese]. Lin Chuang Er Bi Yan Hou Ke Za Zhi 18: 745-6, 766

   Zima TO and Kalousova M (2005) Oxidative stress and signal transduction pathwyas in alcoholic liver disease. Alcoholism, Clinical and Experimental Research 29 (Supplement): 110S-115S